Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension studyMichael R. McClung, Marc P. Bonaca, Stephen D. Wiviott et al.|The Lancet Diabetes & Endocrinology|2019Cited by 171
Ocanacatib antifracture efficacy and saftey in postmenopausal women with osteoporosis: results from the phase III long-term adonacatib fracture trial (LOFT)McClung, A. Lombardi, Bente Langdahl et al.|Open Repository and Bibliography (University of Liège)|2015Cited by 3
Safety and Tolerability of Odanacatib Therapy in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial (LOFT)Socrates E. Papapoulos, Deborah M. Gurner, Michael R. McClung et al.|Data Archiving and Networked Services (DANS)|2014Cited by 3
Safety and efficacy of 36 months treatment of postmenopausal osteoporotic women with PTH (1–84)Robert R. Recker, John Fox, José Zanchetta et al.|Bone|2009Cited by 2
Safety and tolerability of odanacatib therapy in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trialSocrates E. Papapoulos, Deborah M. Gurner, McClung et al.|Open Repository and Bibliography (University of Liège)|2014Cited by 2